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Bilberry Supplementation after Myocardial Infarction
Decreases Microvesicles in Blood and Affects Endothelial
Vesiculation
Paulina Bryl-Górecka,* Ramasri Sathanoori, Lilith Arevström, Rikard Landberg,
Cecilia Bergh, Mikael Evander, Björn Olde, Thomas Laurell, Ole Fröbert, and David Erlinge
Scope: Diet rich in bilberries is considered cardioprotective, but the
mechanisms of action are poorly understood. Cardiovascular disease is
characterized by increased proatherogenic status and high levels of circulating
microvesicles (MVs). In an open-label study patients with myocardial
infarction receive an 8 week dietary supplementation with bilberry extract
(BE). The effect of BE on patient MV levels and its influence on endothelial
vesiculation in vitro is investigated.
Methods and results: MVs are captured with acoustic trapping and
platelet-derived MVs (PMVs), as well as endothelial-derived MVs (EMVs) are
quantified with flow cytometry. The in vitro effect of BE on endothelial
extracellular vesicle (EV) release is examined using endothelial cells and
calcein staining. The mechanisms of BE influence on vesiculation pathways
are studied by Western blot and qRT-PCR. Supplementation with BE
decreased both PMVs and EMVs. Furthermore, BE reduced endothelial EV
release, Akt phosphorylation, and vesiculation-related gene transcription. It
also protects the cells from P2X7-induced EV release and increase in
vesiculation-related gene expression.
Conclusion: BE supplementation improves the MV profile in patient blood
and reduces endothelial vesiculation through several molecular mechanisms
related to the P2X7 receptor. The findings provide new insight into the
cardioprotective effects of bilberries.
1. Introduction
A diet rich in bilberry (Vaccinium myrtillus) or Nordic wild
blueberry has been suggested to be cardioprotective,[1] possibly
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because of their content of polypheno-
lic pigments, anthocyanins, that can be
absorbed by the human intestine and fur-
ther detected in plasma.[1a] However, the
oral bioavailability is low in humans—
after ingestion of 1.2 g anthocyanins
from freeze-dried blueberries, the max-
imal plasma concentration reached
36 nmol L−1.[2] In vitro and in vivo stud-
ies on bilberry-derived compounds have
identified several different possible target
tissues: cardiomyocytes,[3] endothelial
cells (ECs),[4] and leukocytes.[1b] Protec-
tive effects of bilberries are thought to
be mediated by several molecular mech-
anisms involving inhibition of oxidative
stress[1b,4a,5] and inflammation,[6] in-
creased nitric oxide (NO) production,[4b]
and improved lipid profile.[6b,7] Impor-
tantly, studies in humans report im-
provements of numerous cardiovascular
disease (CVD) subsets,[8] for example,
metabolic syndrome,[9] hypertension,[10]
and hypercholesterolemia.[6b] Conse-
quently, a diet rich in anthocyanins
has been advocated as beneficial in
the prevention of CVD and myocardial
infarction (MI).[11]
One of the hallmarks of vascular dysfunction and CVD are
high levels of circulating microvesicles (MVs) in blood. MVs
belong to a group of cell-derived particles, called extracellu-
lar vesicles (EVs), that also include exosomes and apoptotic
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bodies.[12] Although no direct studies have focused on a basic
MV output, the fact that healthy individuals have a steady
MV population indicates that a basal output exists. There are
strong indications that MVs are directly related to patholog-
ical processes.[13] While MVs circulate in the blood of both
healthy individuals and patients with diseases, increased con-
centrations of MVs in plasma have been described in several
vascular-related pathologies, such as coronary artery disease
(CAD),[14] atherosclerosis,[15] hypertension,[16] and MI.[12,17] It
has previously been shown that platelet aggregation is enhanced
ex vivo by MVs originating from activated ECs, via crosslinking
with von Willebrand factor.[18] Endothelial-derived MVs (EMVs)
facilitate proatherogenic processes through many molecular
mechanisms, involving enhanced proliferation of vascular
smooth muscle cells,[19] ECs, activation of clotting cascade, as
well as monocyte interactions with endothelium.[20]
MVs circulating in plasma stem not only from blood cells, like
platelets,[12,17a] but also from the vasculature,mainly ECs.[21] Both
platelet-derived MV (PMV) and EMV blebbing from the cells is
triggered by procoagulant and proinflammatory conditions.[21,22]
The blebbing process is complex and involves numerous intra-
cellular and membrane-bound proteins. As MVs originate di-
rectly from plasmamembranes, membrane-bound receptors and
phospholipids from the cell are retained on the surface.[23] The
molecular cargo of the vesicular lumen includes proteins,[24]
miRNAs,[25] and long non-coding RNAs, all originating from the
mother cell.[26] All these properties render MVs promising in car-
diovascular biomarker discovery.[27]
In vivo experiments showed rapid removal of MVs by liver and
spleen. Some of the proposed mechanisms of MV clearance in-
volve lipid- or protein-directed phagocytosis, depending both on
the origin of MVs, as well as the recipient cell type.[28]
The data presented in this publication comes from a sample
analysis of the already published BilbErry as A dietaRy Supple-
Ment After myocaRdial infarcTion (BEARSMART) clinical trial,
an open-label clinical study in patients with MI, randomized to
8 weeks of dietary supplementation with bilberry extract (BE)
and standard medical therapy or to standard medical therapy
alone.[29] The original study aimed to investigate the effect of BE
supplementation on traditional risk factors, such as cholesterol
levels and exercise capacity in MI patients. The present study
is an exploratory sub-study, evaluating the effects of bilberry
consumption on plasma MV concentration. We found that sup-
plementation with BE significantly reduced PMVs and EMVs,
respectively, in patient plasma.We also investigated the influence
of BE on endothelial vesicle release. Our results showed that
BE decreased endothelial vesiculation through several molec-
ular mechanisms connected with the P2X7 signaling pathway,
such as protein phosphorylation and vesiculation-related gene
transcription.
2. Results
2.1. Study Design and Patient Information
The BEARSMART study, by Arevström et al.[29] is a clinical inves-
tigation, where MI patients were divided into groups receiving
BE dietary intervention or no supplementation. Fifty patients (42
male) of median age 68 years completed the study. Blood sam-
ples were obtained at baseline and after 8 weeks. Patient infor-
mation, BE administration protocol, as well as its characteristics
are included in Tables S1 and S2 and Figure S1, Supporting In-
formation. The aim of the original study was to determine the ef-
fect of BE supplementation in MI patients on cardiovascular risk
markers. The results showed that in the BE-supplemented group
there was a reduction in oxidized low-density lipoprotein (oxLDL)
in plasma.[29] As oxLDL contributes to development of CVD and
has been reported to stimulate vesiculation,[30] MVs appeared as
another possible target affected by BE supplementation. As MV
release is stimulated by proatherosclerotic conditions[21,22] and no
study has investigated the effects of bilberry on plasma MV con-
centration, we analyzed patient plasma samples to measure MV
levels. We also combined the clinical approach with an experi-
mental one by analyzing BE influence on endothelial vesiculation
in vitro.
2.2. Effect of Bilberry Extract on Microvesicles in Plasma
As the BE supplementation in the BEARSMART trial was
associated with a decrease in oxLDL in plasma[29] and oxLDL
stimulates vesiculation,[30] we investigated the effect of BE di-
etary intervention on the concentration of EMVs and PMVs. The
Figure 1. Effect of bilberry extract consumption on plasma MVs. CD42a+ PMV (A) and CD62E+ EMV (B) levels decreased after 8 weeks of BE intake
by MI patients. Box plot. Y-axis values represent MV concentration in 1:4 diluted samples. Mann–Whitney U test. *Statistically significant, p < 0.05. No
supplementation: n = 18, BE supplementation: n = 16.
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BE intervention group had significantly lower concentration of
PMVs in plasma after 8weeks of the supplementation, in contrast
to the control group (204CD42a+MVs per 𝜇L vs 524 CD42a +
MVs per 𝜇L, Figure 1A). Similarly, we observed significantly
reduced levels of plasma EMVs in the BE intervention group
compared to the non-intervention group (193CD62E+ MVs per
𝜇L vs 237 CD62E+MVs per 𝜇L, Figure 1B).
As the majority of subjects were male, we additionally ana-
lyzed the impact of BE on plasma MV levels after exclusion of
the female patients. Similarly to the analysis of all patients the
BE intervention group exhibited a significantly lower concentra-
tion of PMVs in plasma in contrast to the control group after 8
weeks of the supplementation (208 CD42a+ MVs per 𝜇L vs 492
CD42a+ MVs per 𝜇L, Figure S4, Supporting Information). We
also observed significantly reduced levels of plasma EMVs in the
BE intervention group compared to the non-intervention group
(187 CD62E+ MVs per 𝜇L vs 237 CD62E+ MVs per 𝜇L, Figure
S4, Supporting Information).
2.3. Nanoparticle Tracking Analysis of Plasma Extracellular
Vesicles
NanoSight-based nanoparticle tracking analysis (NTA) was per-
formed to verify the presence of CD62E+ and CD42+ EVs in our
sample set. The analysis of non-fluorescent vesicles revealed two
major particle peaks between 200 and 400 nm that correspond
to MVs (Figure 2A). We were also able to confirm the presence
of CD62E+ EMVs (Figure 2B) and CD42a+ PMVs (Figure 2C).
For both CD62E+ and CD42a+ EVs, the peak was at 100–150 nm
that represents very small MVs. Moreover, CD62E+ EVs appear
as 200–500 nm peaks and CD42a+ EVs as 300–500 nm that also
matches the MV size.
2.4. Bilberry Extract Effect on Endothelial Vesiculation
Based on the BE influence on plasma MVs, we designed in vitro
experiments to determine if BE acts directly on ECs and leads to
a decreased vesiculation. We performed a dose response of BE
on human umbilical vein endothelial cell (HUVEC) viability and
proliferation and the concentration of 1000 µg mL−1 did not ex-
hibit any toxic effects (Figures S2 and S3, Supporting Informa-
tion). This led to the use of this concentration, and lower BE doses
were not further investigated.
To induce vesicle release from ECs, the endothelial P2X7 re-
ceptor was activated with 2′(3′)-O-(4-benzoylbenzoyl)adenosine-
5′-triphosphate tri(triethylammonium) salt (bzATP), as this re-
ceptor is known to take part in EV formation and budding.[31]
To visualize EC vesiculation, we performed calcein staining of
HUVECs.[32] The cells were pre-incubated with BE and stimu-
lated with P2X7 agonist bzATP or inhibited with P2X7 antagonist
AZ11645373.
BE reduced HUVEC vesiculation (Figure 3), measured as
calcein fluorescence in the culture medium. The P2X7 ago-
nist bzATP stimulated vesiculation, which was blocked by the
P2X7 antagonist AZ11645373. It is noteworthy that similar re-
sults were seen with BE pre-incubation and subsequent agonist
stimulation.
Figure 2. Nanoparticle tracking analysis of patient plasma. A) Concentra-
tion of all EVs (unstained). B) Concentration of CD62E+ EVs. C) Concen-
tration of CD42a+ EVs.
2.5. Bilberry Extract Effect on Protein Phosphorylation
Based on the above results and current knowledge about P2X7
and anthocyanins, we selected Akt and p38 as candidate proteins
for further investigation, as both are involved in P2X7 signaling
pathways and vesiculation.[33] Also, both Akt and p38 phosphory-
lation status has previously been reported to be affected by BE.[34]
As protein phosphorylation is a moderately rapid reaction, we
chose 3 and 6 h as time points. None of the tested BE concentra-
tions exhibited toxic effect on HUVECs, and we thus chose the
highest dose, 1 mg mL−1, for further experiments. BE decreased
Akt phosphorylation after 3 h, but not after 6 h (Figure 4A,B, and
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Figure 3. HUVEC vesiculation in the presence of BE, bzATP, and P2X7 an-
tagonist. P2X7 activator bzATP increased HUVEC vesiculation via a P2X7-
dependent mechanism. BE decreased basic vesiculation of HUVECs. Pre-
incubation with BE was able to inhibit the effect of bzATP on HUVECs.
Data is represented as normalized calcein fluorescence. Error bars repre-
sent SD. One-way ANOVA with FDR correction. *Statistically significant,
p < 0.05, n = 4.
Figure S5, Supporting Information). However, p38 phosphoryla-
tion was unchanged at both time points (Figure 4C,D), suggest-
ing that this protein is not involved in BE-stimulated vesiculation
decrease.
2.6. Bilberry Extract Effect on P2X7 Transcription
Next, we investigated if the decrease in vesiculation also could
be associated with a BE-induced effect on P2X7 expression. A
decline in P2X7 mRNA in HUVECs was observed following BE
treatment (Figure 5). Interestingly, a similar picture was found
with bzATP alone, which could be explained by an inhibitory ef-
fect of P2X7 stimulation on its transcription.
[35] BE or BE plus
antagonist with subsequent bzATP treatment also profoundly de-
creased P2X7 expression.
2.7. Bilberry Extract Effect on Transcription of
Vesiculation-Related Genes
Last, we examined the mechanism of BE inhibition of vesicula-
tion. Rab27b, Rab27a, SMPD1, and ARF6 genes were chosen as
candidate genes, as the proteins are involved in EV release.[36] BE
reduced expression of Rab27b and Rab27a and prevented bzATP-
induced increase of Rab27b, Rab27a, and SMPD1 gene expres-
sion (Figure 6 ). We did not obtain any conclusive results for
ARF6 transcription, as it was decreased after all combinations of
treatments and did not present any obvious pattern.
3. Discussion
Bilberry is a widely consumed berry with suggested cardiovas-
cular health benefits.[1a,37] In this study, we investigated if BE
dietary intervention improves EMV and PMV concentrations in
plasma of MI patients. The mechanism whereby it affects en-
dothelial vesiculation in vitro was also analyzed. We found that
BE supplementation reduced MV levels in patient plasma. Fur-
thermore, it decreased P2X7-dependent endothelial EV release,
Akt phosphorylation, and vesiculation-related gene expression.
In the BEARSMART study, Arevström et al. observed a positive
influence of BE on oxLDL levels in patient plasma.[29] While it is
well known that oxLDL plays a role in atherosclerosis progression
and promotes EV release,[30] a possible link between vesiculation
and BE has not been addressed before.
Our results clearly showed that BE supplements significantly
decreased PMV levels in plasma. Yang et al. reported inhibition of
platelet activation by the anthocyanin delphinidin-3-glucoside,[38]
a pigment also present in bilberries,[39] which could explain the
reduced vesiculation, and thus the lower PMV counts we ob-
served in patient plasma. This is further supported by studies by
Erlund et al. and Thompson et al., reporting reduced platelet ag-
gregation after 8 and 4 weeks of diet with berry extracts (mixtures
of bilberries, lingonberries, strawberries, black currants, choke-
berries, and raspberries).[10,40] Furthermore, Song et al. showed
a reduction of platelet granule secretion after in vitro incubation
with an anthocyanin mixture.[41]
Similar to the PMVs, plasma EMVs were also significantly re-
duced. Malvidin, an anthocyanidin highly abundant in bilber-
ries, is transported into ECs,[42] where it inhibits oxidative stress,
promotes NO production, and decreases inflammation.[43] This
in turn leads to diminished activation, thus the procoagulant
and proinflammatory state of ECs,[44] and decreased E-selectin
(CD62E) presentation.[45] Furthermore, reduced endothelial ac-
tivation decreases membrane blebbing and, as a consequence,
vesiculation.[21]
Our results demonstrate a potent clinical effect of BE sup-
plementation on plasma MV levels in MI patients. As MVs are
directly connected to pathological processes[13] and increased
levels of MVs in plasma are associated with atherosclerosis-
related pathologies,[12,14–17] the data presented here points at the
preventive role of bilberries in CVD. Since there is very limited
information regarding the influence of food-derived compounds
on EV release in vitro and in vivo, this further supports the im-
portance of our findings for dietary guidance of cardiovascular
patients, as well as healthy individuals.
As BE dietary intervention resulted in a decrease of EMV con-
centration in patient plasma, we decided to investigate how it af-
fects endothelial vesiculation in vitro. P2X7 receptor was selected
as a target for our experimental setup due to its presence in HU-
VECs and its verified contribution to EV release.[31a–c,46] Since the
potential effects of BE on platelets and PMV release have been
previously described, we decided to focus our research on ECs.
Thompson et al. reported that a 4 week bilberry and black currant
extract supplementation inhibited ADP-induced platelet aggrega-
tion ex vivo[40] that is directly linked to P2Y12 receptor-induced
platelet activation.[47]
The concentration of BE used in the in vitro study (1mgmL−1),
as well as the time pattern of the experiments (24 h) differed from
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Figure 4. Effect of bilberry extract on Akt and p38 signaling in endothelial cells. 3 h incubation with BE decreased Akt phosphorylation in HUVECs (A),
while 6 h incubation had no effect (B). Lack of BE influence on p38 phosphorylation was observed (C and D). Error bars represent SD. One-way ANOVA
with FDR correction, n = 3. *Statistically significant, p < 0.05; pAkt, phosphorylated Akt; pp38, phosphorylated p38.
the clinical design (40 g daily for 8 weeks), as mentioned in the
Dosage Information section. Due to the nature of in vitro cul-
tured ECs, it was not feasible to perform experiments using the
same time frame, as the clinical study. Thus, to mimic long-term
incubation time, we used the highest tested concentration for fur-
ther experiments. However, oscillations of low concentration of
BE and its metabolites in blood in the clinical study may act dif-
ferently on vesiculation, compared to our in vitro experimental
design.
Our results showed that the P2X7 agonist, bzATP, increased
endothelial vesicle release and that AZ11645373 inhibited this re-
sponse. Importantly, basicHUVEC vesiculationwas decreased by
incubation with BE alone, but BE pre-incubation was able to pre-
vent the effect of subsequent agonist stimulation. These results
show that BE affects non-stimulated, as well as P2X7-stimulated
vesicle release in ECs.
After establishing the inhibitory effect of BE on EC vesicu-
lation, we next investigated the potential mechanisms. Akt is
a downstream target of P2X7 in astrocytes
[33c] and Hao et al.
demonstrated inhibition of Akt in cardiac fibroblasts after pre-
treatment with berry-derived malvidin.[34c] Akt was also reported
to take part in vesiculation of red blood cells.[33d] Our results
showed that Akt phosphorylation was diminished after 3 h of
incubation with BE, but returned to the original phosphoryla-
tion state after 6 h. In line with our findings, Matsunaga et al.
reported decreased Akt phosphorylation after BE treatment of
HUVECs.[48]
Activation of p38 has previously been reported to increase EV
production.[49] Furthermore, p38 activation in TNF𝛼-stimulated
ECs resulted in EMV production.[49] Anthocyanins are known to
enter ECs through bilitranslocases[42,50] andOgawa et al. reported
that BE decreases p38 phosphorylation in retinal cells.[34d] We
have previously shown that p38 is involved in P2X7-related EC
activation after high glucose and palmitate treatment.[33b] More-
over, p38 takes part in P2X7 signaling pathway leading to MV
release from microglia.[33a,36b] Surprisingly, we did not observe
any significant effect of BE on pp38 after 3 and 6 h of stimula-
tion. A possible explanation is that in our experimental setup the
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Figure 5. P2X7 expression in HUVECs in the presence of BE and bzATP.
Both bzATP and BE decreased P2X7 expression. Pre-incubation with BE
was able to additionally decrease P2X7 expression in HUVECs, following
agonist stimulation. Error bars represent SD. One-way ANOVA with FDR
correction, n = 4. *Statistically significant, p < 0.05.
phosphorylation of p38 is not involved in BE-evoked decrease in
vesiculation or that the time frame of the experiments did not
allow us to detect such changes.
Since it has been demonstrated that activation of the PI3K/Akt
pathway enhances transcription of P2X7 receptor in neuroblas-
toma cells,[51] we next investigated if BE is capable of modulating
the P2X7 expression level. We found that incubation with BE sig-
nificantly lowered the basic levels of P2X7 mRNA which, in turn,
can in part explain part of the inhibitory effect of BE on Akt phos-
phorylation. A similar inhibitory effect was obtained with bzATP
alone, which is well in line with the report of Salvestrini et al.,
who described a negative feedback effect of P2X7 stimulation on
its transcription.[35]
The effect of BE on transcription of genes related to EV re-
lease was then further investigated. Four genes were selected:
Rab27b, Rab27a, SMPD1, and ARF6, that all have been reported
to take part in EV release.[36] Rab27b and Rab27a were chosen
as potential candidates to examine the effect of BE, as they con-
trol different stages of EV release.[36d] The results showed a gene
expression pattern matching the EV release results. BzATP sig-
nificantly increased Rab27b and Rab27a expression in HUVECs,
while pre-incubation with BE alone decreased it.
We finally investigated two other genes, SMPD1 and ARF6.
SMPD1 was chosen as it was described to trigger MV release
from glial cells via P2X7-dependent phosphorylation of p38.
[36b]
Although neither P2X7 agonist nor BE had any effect on p38
phosphorylation, the SMPD1 transcription was affected by both,
thus suggesting a p38-independent mechanism. No conclusive
results were obtained regarding ARF6 transcription, as its levels
were decreased after all treatments, without any evident pattern.
Based on our results, we suggest a model where anthocyanins
from BE decrease Akt phosphorylation and P2X7 transcription,
which in turn reduces EV release (Figure 7). We also speculate
that the observed BE in vitro influence on EC vesiculation reflects
the decreased EMV levels in plasma from BE-treated patients.
However, as the concentration of BE used in the in vitro study
was higher than the concentration in the patient blood, other
mechanisms could also be responsible for the decrease in plasma
MVs. BE-derived anthocyanins exhibit a number of antioxidant
properties.[1a] Thus, while circulating in blood, anthocyanins
could act locally as free radical scavengers. Free radicals can acti-
vate ECs via decreasingNOproduction;[44] and antioxidants, such
as anthocyanins, could reduce radical activation-related MV re-
lease by the endothelium.[21] If taken up via bilitranslocases or by
othermechanisms, anthocyanins could also potentially influence
other vesiculation-related pathways within ECs. There is also the
possibility that an active uptake, in combination with a longer
time frame, results in an intracellular accumulation of BE that in
turn could explain the different dose/response findings in the in
vivo study.
Furthermore, BE is a complex mixture that undergoes molec-
ular transformations in the body, and anthocyanin-derived
metabolites could also potentially play an important role in re-
ducing vesiculation. Edwards et al. reported an inhibitory ef-
fect of vanillic acid, a metabolite of cyanidine-3-glucoside, on
NADPH oxidase (enzyme producing superoxide anions) ex-
pression in HUVECs.[52] Thus anthocyanin metabolites could
also act against vascular activation and MV release into the
circulation.
Most of the currently available clinical trials point to favor-
able effects of berries in CVD patients, compared to healthy
subjects.[53] As an increase in the vesicle formation reflects the
endothelial activation status in a negative way, the reduction in
vesiculation can be interpreted as CVD protective. Thus, long-
term intake of anthocyanin-rich diet in an otherwise healthy
population is probably beneficial formaintaining proper vascular
status and preventing development of CVD in the future.
The major strength of this study is that it combines both clin-
ical, as well as experimental findings. Another strength was the
rapid initiation of BE administration within 24 h after PCI. The
original design of the study involved administration of placebo to
the control group subjects. However, the placebo powder caused
gastrointestinal stress, and the study was halted and restarted
with new study subjects to avoid the side effects.[29] Furthermore,
a larger population would have allowed for a better examination
of the subgroups.
The effect of bilberry intake on MV concentration in plasma
has not been explored before. Here we show the BEARSMART
clinical trial that investigated if an 8 week BE consumption af-
fects MV status in patients after MI. According to our results,
such dietary intervention decreased PMV and EMV levels in pa-
tient plasma. Since themajority of the studied subjects weremale
and because men and women differ in morbidity in CVD, larger
studies across both genders should be performed to establish ef-
fectiveness of BE on MI patients. Moreover, in vitro studies re-
vealed that BE reduced EV release by ECs. Further experiments
revealed that BE decreased Akt phosphorylation, as well as tran-
scription of P2X7 and vesiculation-related genes. BzATP stim-
ulation of HUVECs increased vesiculation and the expression
of Rab27b, Rab27a, and SMPD1 genes, while BE pre-incubation
prevented it. All these findings show that P2X7 receptor is im-
portant for EC vesiculation and BE reduces EV release through
different molecular mechanisms, related to the P2X7 signaling
pathway.
Mol. Nutr. Food Res. 2020, 2000108 © 2020 The Authors. Published by Wiley-VCH GmbH2000108 (6 of 10)
www.advancedsciencenews.com www.mnf-journal.com
Figure 6. BE influence on vesiculation-related gene expression in the presence of bzATP and P2X7 antagonist. BzATP increased A) Rab27b, B) Rab27a,
and C) SMPD1 expression in HUVECs via P2X7-dependent mechanism. BE decreased basic expression of Rab27b (A) and Rab27a (B). Pre-incubation
with BE was able to inhibit the effect of bzATP on Rab27b, Rab27a, and SMPD1 genes. D) ARF6 expression following the treatments did not present any
pattern. Error bars represent SD. One-way ANOVA with FDR correction, n = 4. *Statistically significant, p < 0.05.
In conclusion, BE reduced both EMVs and PMVs in the plasma
ofMI patients. A decrease in EMV levels is caused by intracellular
mechanisms, known to be important for vesiculation. Our find-
ings also provide new insight into the protective effects of bilber-
ries, which can have impact on vascular health of CVD patients.
4. Experimental Section
Study Design: The BEARSMART trial was an open-label, randomized
clinical study (ClinicalTrials.gov identifier: NCT01958034), where patients
with MI, after providing informed consent, were randomized within 24 h
of percutaneous coronary revascularization in a 1:1 ratio to BE supple-
mentation or no dietary intervention. All subjects received standard med-
ical treatment. The trial was approved by the regional ethics review board
in Uppsala, Sweden (Drn: 2013/311). Patient information, BE character-
istics, as well as administration protocols are included in Tables S1 and
S2 and Figure S1, Supporting Information. Subject exclusion criteria had
previously been described.[29] Patients randomized to BE-supplemented
group ingested three doses of 13.3 g of BE each day, totaling 40 g daily
that corresponded to 480 g fresh bilberries. The extract (Immune, Swe-
den, www.immun.se) contained 2250 mg of anthocyanins per 100 g; thus,
the patients consumed 300 mg anthocyanins in a single dose.
Sample Collection: Citrated blood samples were collected at baseline
and after 8 weeks. The blood was drawn according to hospital proce-
dures and regulations, and centrifuged within 30 min. Before freezing at
−80 °C, plasma samples were centrifuged to avoid contamination with
platelet fragments. The obtained cell-free plasmawas aliquoted and stored
at −80 °C.
Extracellular Vesicle Preparation with Acoustic Trapping Platform: The
AcouTrap acoustic trapping platform (AcouSort AB, Sweden) for EV en-
richment from plasma samples had previously been described.[27b,54]
In the acoustic trapping method of MV enrichment, 12 µm polystyrene
beads, so-called seed particles, were retained within a glass capillary by an
acoustic standing wave. Diluted plasma sample was then aspirated and
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Figure 7. Proposed molecular mechanisms of BE-induced reduction of vesicle release. Previous results demonstrated that anthocyanins (AC) enter
ECs via bilitranslocases (1) and inhibit PI3K activation (2). This prevents Akt phosphorylation and reduces P2X7 transcription (3) that stands in line
with our results. According to the literature, P2X7 signaling pathway leads to Akt phosphorylation and further EV release (4). Moreover, our data shows
that P2X7 cascade also augments transcription of vesiculation-related genes Rab27b and Rab27a that are inhibited by BE treatment (5), possibly due
to a decrease in P2X7 expression. We propose that P2X7-evoked increase in Rab27b and Rab27a transcription reflects increased cellular demands after
P2X7-stimulated vesiculation.
MVs were retained within the cluster of the seed particles. For the flow cy-
tometry experiments, the samples were thawed at 37 °C and diluted 1:2
in PBS. 50 µL, of the diluted plasma was aspirated into the seed particle
cluster, at a speed of 25 µL min−1. The trapped MVs were then washed
with 50 µL of PBS and released in 100 µL of PBS.
Sample Exclusion Criteria: Some samples were excluded from further
analysis, because of the physical properties of these samples (e.g., high
viscosity and lipid content) that interfered with platelet elimination dur-
ing centrifugation. Due to these issues, values from 16 and 18 subjects in
the bilberry intervention and the non-intervention groups were reported,
respectively.
Flow Cytometry: 100 µL of eluted MV suspension was stained with
3 µL of PE-conjugated antibodies (Abs) against CD62E or glycoprotein IX
(CD42a) (BD Biosciences, US). Samples were analyzed with Accuri C6 (BD
Biosciences, US) cytometer as previously described.[27b]
Nanoparticle Tracking Analysis: Trapped plasma samples were diluted
withDPBS, stainedwith CD62E and CD42a Abs, further diluted withDPBS,
and analyzed by NanoSight LM10 (Malvern, UK) equipped with 488 nm
blue laser. Samples were measured for 60 s in quadruplicates using man-
ual gain, camera level set to 5 and detection threshold to 33 (unstained),
or camera level set to 13 and detection threshold to 4 (stained). Ab-only
and PBS controls were used to ensure rigorous measurement of the vesi-
cles. The obtained data was analyzed with NTA 3.2.16 software (Malvern,
UK).
Dosage Information: BE was prepared from V. myrtillus as described
by Arevström et al.[29] For measuring the effect on in vitro toxicity and
cell proliferation, HUVECs were seeded in 6-well dishes covered with
attachment factor and cultured in Medium 200 with LSGS (final serum
concentration 2%) and gentamycin/amphotericin (Thermo Fisher Scien-
tific, US). 100 mg of bilberry powder was diluted in 1 mL water, incubated
in 60 °C for 1 h, and centrifuged at 20 000 × g for 10 min. The resulting
supernatant (the BE) was aspirated and added to fresh culture medium to
prepare BE-containing medium. The mixture was further incubated with
confluent cells to obtain 1000, 100, and 10 µg mL−1 final concentrations.
After 24 h incubation, the cells were harvested, stained with trypan blue for
viability and cell proliferation assessment. 1000 µg mL−1 BE was chosen
as the working concentration for further experiments due to the lack of
toxic effects on the cells (Figures S2 and S3, Supporting Information).
The concentration of BE chosen for the in vitro study (1 mgmL−1 BE, thus
0.0225 mg mL−1 anthocyanins) clearly exceeded the concentration of
anthocyanins in the clinical study (300 mg three times per day). The rea-
sons for this were that both cellular context and time frame were different
from the clinical study (hours instead of weeks). According to the liter-
ature, 1200 mg of blueberry anthocyanins resulted in a maximal plasma
concentration of 36 nmol L−1.[2] The concentration of total anthocyanins
in blood was not determined in the original study but, based on the
report by Manach et al.,[2] it could be assumed that the maximal plasma
concentration of anthocyanins could end up to be 9 nmol L−1, whereas
for the in vitro study it would be about 12 µmol L−1 (22.5 µg mL−1).
However, in the original study the concentrations of anthocyanin-derived
metabolites in blood were measured and high concentrations were
found. For example, the concentrations reached 875 nmol L−1 for vanillic
acid-4-O-sulfate, 21 nmol L−1 for gallic acid, 26.9 nmol L−1 for caffeic acid
4-𝛽-d-glucuronide and, 6.4 nmol L−1 for p-coumaric acid.[29] All the above-
mentioned compounds were significantly different from the control group.
Compound Effect on Endothelial Vesiculation: 12 × 103 HUVECs were
seeded in 12-well dishes and cultured for 24 h. 1000 µg mL−1 BE or fresh
culture medium (control) were added and cultured for 24 h. 300 µm of
P2X7 agonist bzATP (Sigma-Aldrich, Germany) and 100 nm of P2X7 an-
tagonist AZ11645373 (Sigma-Aldrich, Germany) were prepared from stock
solutions in the culture medium. The diluted compounds or fresh culture
mediumwere added to the calcein-stained cells (see below) and incubated
for the next 24 h. Three different HUVEC lots below passage 4 were used
in the in vitro experiments.
Calcein Staining: 2 mm calcein AM (Thermo Fisher Scientific, US)
stock was prepared in DMSO and serially diluted in HBSS with 0.1% BSA
to obtain 2 µm working solution with trace amounts of DMSO. After the
compound incubation, the cells were washed twice withHBSS. 1mL of cal-
cein solution was added per well and the cells were incubated at 37 °C for
15 min. The cells were then washed with HBSS and fresh culture medium
was added. After 24 h incubation, the medium was collected, centrifuged
at 2000 × g for 10 min at 4 °C to remove cellular debris and analyzed using
CLARIOstar plate reader (BMG Labtech, Germany). All values were nor-
malized to that of the control cells.
Western Blot: HUVECs were plated in 6-well plates. After 24 h,
1000 µg mL−1 BE was added and the cells were harvested after 3 or 6 h
Mol. Nutr. Food Res. 2020, 2000108 © 2020 The Authors. Published by Wiley-VCH GmbH2000108 (8 of 10)
www.advancedsciencenews.com www.mnf-journal.com
with 200 µL RIPA buffer (Cell Signaling, US) containing phosphatase in-
hibitors. The samples were vortexed, incubated at 4 °C for 5min, sonicated
and centrifuged at 15 000 × g for 10 min at 4 °C. The lysates were then
transferred to new tubes and kept frozen at −80 °C. Protein concentration
was measured using BCA Protein Assay Kit (Thermo Fisher Scientific, US)
according to themanufacturer’s instructions. 10 µg of protein were loaded
on pre-cast polyacrylamide midi gels (Thermo Fisher Scientific, US). Elec-
trophoresis was performed at 150 V and dry transfer was performed on
nitrocellulose membrane via iBlot 2 transferring system (Thermo Fisher
Scientific, US). The nitrocellulose membrane was blocked with blocking
buffer (Thermo Fisher Scientific, US) for 1 h. Primary Abs against phospho-
Akt (pAkt) clone D9E, Akt clone 11E7, phospho-p38 (pp38) clone D3F9,
p38 clone D13E1, and 𝛽-actin clone 13E5 (Cell Signaling, US) were di-
luted as per manufacturer’s instructions in 5% BSA in TBST and incubated
overnight at 4 °C. Secondary goat anti-rabbit Ab (Thermo Fisher Scientific,
US) was diluted 1:2500 in 5% BSA in TBST and incubated for 1 h at room
temperature. The bands were visualized with Pico Chemiluminescent As-
say (Thermo Fisher Scientific, US) and analyzed with Odyssey Fc (LI-COR,
US) and Image Studio v. 3.1.4.
Quantitative Real-Time PCR: HUVECs were plated and treated with
1000 µg mL−1 BE or combinations of bzATP and AZ11645373 as previ-
ously described. The cells were harvestedwith 700 µLQIAzol (Qiagen, Ger-
many), incubated for 5 min in RT, and frozen at −80 °C. RNA isolation was
performed withmiRNeasy kit with DNase digestion (Qiagen, Germany) as
per manufacturer’s instructions. High Capacity RNA to cDNA kit (Thermo
Fisher Scientific, US) was used for reverse transcription. The mRNA lev-
els for P2X7, Rab27b, Rab27a, SMPD1, and ARF6 with GAPDH as a refer-
ence gene were assessed using TaqMan Fast Universal PCR Master Mixes
(Thermo Fisher Scientific, US) and 20 ng template as per manufacturer’s
instructions.
Statistics: Shapiro test of normality showed that theMV concentration
in patient plasma was not normally distributed. Thus, Mann–Whitney U
test was applied to compare differences between BE supplementation and
no supplementation after 8 weeks. In vitro compound effects on ECs were
analyzed with one-way ANOVA with false discovery rate (FDR) correction
of Benjamini and Hochberg. p-values < 0.05 were considered statistically
significant. All analyses were performed with GraphPad Prism software
version 7.0a (GraphPad Software Inc., USA).
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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